Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myelomaTorben Plesner, Paul G. Richardson, Antonio Palumbo et al.|Blood|2016Cited by 110
Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple MyelomaTorben Plesner, Paul G. Richardson, Hendrik‐Tobias Arkenau et al.|Blood|2014Cited by 49
Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)Torben Plesner, Paul G. Richardson, Hendrik‐Tobias Arkenau et al.|Blood|2015Cited by 40
Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.Torben Plesner, Paul G. Richardson, Hendrik‐Tobias Arkenau et al.|Journal of Clinical Oncology|2014Cited by 36